지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2013.3
- 수록면
- 27 - 34 (8page)
이용수
초록· 키워드
오류제보하기
This study was conducted to investigate the potential embryo-fetal toxicity and toxicokinetics of the antimalarial agent artesunate (ARTS) in Sprague-Dawley rats. Pregnant rats were administered ARTS daily from gestational day 6~15 via oral gavage, at test doses of 0, 2, 4, or 8 mg/kg (22 females per group). The fetuses were examined for external, visceral, and skeletal abnormalities on gestational day 20. With regard to the dams, there were no deaths, treatment-related clinical signs, changes in body weight, or food intake in any of the treatment groups. There were no treatment-related gross findings at necropsy in any treatment group. In the 8 mg/kg group, there was a decrease in gravid uterine weight and in the weight of female fetuses. There was also an increase in fetal deaths (primarily late resorptions) and an increase in post-implantation losses (37%) at 8 mg/kg. An increase in the incidence of visceral and skeletal variations at 4 and 8 mg/kg was observed. These defects included minor changes in the appearance of the kidney and thymus, as well as absent ribs or thoracic vertebrae. Toxicokinetics were assessed in a parallel study, using 4 mated females per group. Using liquid chromatography-mass spectrometry (LC-MS) analysis, the concentration of ARTS and its metabolite dihydroartemisinin (DHA) were quantified in plasma from rats on gestational days 5, 6, 10, and 15. Amniotic fluid was assayed for ARTS and DHA on gestational day 15. There was evidence of rapid conversion of ARTS to the metabolite DHA in maternal plasma, since ARTS could not be consistently detected in plasma at the three doses tested. ARTS and DHA were not detected in amniotic fluid at gestational day 15, indicating limited placental transfer of the two agents. The embryofetal no-observable-adverse-effect level (NOAEL) of the test item was considered to be 8 mg/kg/day for dams, and 2 mg/kg/day for embryo-fetal development.
목차
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (19)
참고문헌 신청
Bialek, R. / 1999 / Parasitic diseases in pregnancy and congenital parasitos. Part 1. Protozoan infections (Review, German) / Z Geburthilfe Neonatal. 203:55~62
Deen, J. L. / 2001 / The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy / Trans. R. Soc. Trop. Med. Hyg. 95:424~428
White, N. J. / 1999 / Averting a malaria disaster / Lancet 353:1965~1967
Ilett, K. F. / 2002 / The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria / Br. J. Clin. Pharmacol. 53:23~30
Sarciron, M. E. / 2000 / Effect of artesunate, dihydroartemisinin, and an artesunate- dihyroartemisinin combination against Toxoplasma gondii / Am. J. Trop. Med. Hyg. 62:73~76
Deen, J. L. / 2001 / The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy / Trans. R. Soc. Trop. Med. Hyg. 95:424~428
White, N. J. / 1999 / Averting a malaria disaster / Lancet 353:1965~1967
Ilett, K. F. / 2002 / The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria / Br. J. Clin. Pharmacol. 53:23~30
Sarciron, M. E. / 2000 / Effect of artesunate, dihydroartemisinin, and an artesunate- dihyroartemisinin combination against Toxoplasma gondii / Am. J. Trop. Med. Hyg. 62:73~76
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2014-510-003159924